IDYA · IDEAYA Biosciences, Inc. · Stock research

Current Thesis

The leg being bought is regulatory, not clinical: the registrational Phase 2/3 OptimUM-02 trial of darovasertib + crizotinib in first-line HLA*A2-negative metastatic uveal melanoma already hit (HR 0.42; median PFS 6.9 vs 3.1 months; ORR 37.1% vs 5.8%, 5 complete responses; ASCO late-breaking oral 2026-06-01), and the question now is whether the rolling NDA under FDA Oncology Center of Excellence Real-Time Oncology Review completes inside the guided H2 2026 window. The 2026-08-04 Q2 print reaffirmed that language and put cash, cash equivalents and marketable securities at approximately $1.24 billion as of 2026-06-30, with runway guidance into 2030 unchanged. What has changed since late July is timing rather than thesis: the print is behind the tape, and the next dated company event is the ESMO Congress in Madrid in October. Price closed $36.30 on 2026-08-14, 10.4% under the 52-week high of $40.51, with RSI(14) at 46.0 and a 3-month return of +28.7% — a name working over the quarter but drifting inside its post-readout range with nothing scheduled to resolve.

Bullish and bearish views on IDEAYA Biosciences, Inc.

The model's bull view on IDEAYA Biosciences, Inc. (IDYA), in brief: OptimUM-02 delivered the largest binary in the story on 2026-06-01: HR 0.42, median PFS 6.9 vs 3.1 months, ORR 37.1% vs 5.8%, five complete responses in the combination arm — a first-line setting with no approved standard for HLA*A2-negative patients. The bear view: The loss line is widening faster than the revenue line: Q2 net loss $112.5M vs $98.5M in Q1; R&D $108.7M vs $95.7M; G&A $22.5M vs $19.4M. Both cases follow in full.

Bull Case

• OptimUM-02 delivered the largest binary in the story on 2026-06-01: HR 0.42, median PFS 6.9 vs 3.1 months, ORR 37.1% vs 5.8%, five complete responses in the combination arm — a first-line setting with no approved standard for HLA*A2-negative patients.
• The submission is in flight, not planned. Rolling NDA under RTOR with the first pre-submission module in May 2026, fast track designation, and completion reaffirmed for H2 2026 at the 2026-08-04 print.
• Balance sheet removes financing as a live variable: ~$1.24B cash and marketable securities at 2026-06-30 against Q2 R&D of $108.7M and G&A of $22.5M, runway guided into 2030.
• ESMO in October carries three darovasertib datasets (OptimUM-01 in the HLA*A2-positive subset, neoadjuvant OptimUM-09) plus the Hengrui-sponsored IDE849 Phase 1 update; per the 2026-08-04 release, OptimUM-01 data is included in the NDA submission to support discussions that could widen the labeled indication.
• Additional shots on goal added inside the quarter: a Roche clinical collaboration announced 2026-08-04 pairing IDE892 (PRMT5) with RG6505 (pan-RAS) in MTAP-deleted, RAS-mutant pancreatic cancer, Phase 1 combination targeted H2 2026; first patient dosed 2026-06-15 in the IDE892 + IDE397 Phase 1; IDE849 registrational trial initiation targeted by year-end 2026.
• Partner economics reduce the spend: Servier (Aug 2025) contributed $210M upfront, up to $320M in milestones, double-digit royalties and shared darovasertib development cost. Collaboration revenue stepped from $6.6M in Q1 2026 to $8.9M in Q2, beating the $5.015M consensus reported 2026-08-04.
• Street targets remain above spot after the print: Truist Buy at $59 and Wedbush Outperform at $60, both 2026-08-05; RBC Outperform $48 (2026-07-07, cut from $53). The GSK acquisition of Nuvalent for $10.6B announced 2026-06-09 anchors the takeout comparison in near-approval precision oncology, and IDEAYA runs an existing GSK Pol-theta collaboration.

Bear Case

• The loss line is widening faster than the revenue line: Q2 net loss $112.5M vs $98.5M in Q1; R&D $108.7M vs $95.7M; G&A $22.5M vs $19.4M. Reported EPS of $(1.22) missed the $(1.09) consensus on 2026-08-04.
• Revenue is collaboration and milestone recognition, not product. $8.9M in a quarter with a $112.5M loss is not a demand signal, and its quarter-to-quarter shape is set by partner accounting.
• Supply was issued into the readout. The June offering priced at $27.00 on 2026-06-09 — eight days after the ASCO data — Weighted-average shares outstanding were 92.1M in Q2.
• Target revisions have been two-way and mostly lower off the highs: RBC $53 → $48 (2026-07-07), Truist $63 → $59 (2026-08-05), against Wedbush $58 → $60 (2026-08-05). Dispersion of $48–$60 across four actions in five weeks is a spread on the same filed facts.
• H2 2026 filing completion is guidance. RTOR shortens review mechanics but neither acceptance nor a PDUFA date exists until the rolling submission is complete and accepted, so the interval between now and any dated FDA clock is open-ended.
• Uveal melanoma is a small indication and IDEAYA has never launched a product. Nothing in the Q2 disclosure quantifies commercial infrastructure spend or a launch revenue expectation.
• Between 2026-08-04 and the ESMO window there is no company-controlled dated event, which leaves the tape to sector beta.

Setup & Price Structure

• Reference: the 2026-08-14 close of $36.30, 10.4% below the 52-week high of $40.51, +28.7% over three months, RSI(14) 46.0. Momentum is neutral and the name sits mid-range between the June issuance price of $27.00 and the July high.
• The narrative is maturing. What dates it — the pivotal readout printed 2026-06-01 and is fully in the tape; the financing cleared 2026-06-09; the Q2 confirmation landed 2026-08-04; sell-side response since has been target maintenance rather than new initiation (2026-07-07 and 2026-08-05 actions), and the price has faded ~10% off the high rather than extending. The narrative still works but the new-attention phase is behind it.
• Positioning observables, stated as observables: analyst actions clustered in two tight windows (two on 2026-07-07, two on 2026-08-05); pre-planned, and executed within $0.50 of the 52-week high; the company itself sold 12.8M shares and pre-funded warrants at $27.00 within days of the ASCO print. No earnings date falls inside the next 30 days, so the usual pre-print binary is absent from the current window.
• The $27.00 June offering price is where the last block of marginal supply cleared. A weekly close below $30 would mark roughly a halfway retrace from the $40.51 high back toward that shelf and would break the post-OptimUM-02 consolidation.

Catalyst Calendar (next 30 days)

• No confirmed company-dated event falls between 2026-08-16 and 2026-09-15. Q2 was reported 2026-08-04; the next scheduled items sit in October and beyond. Anything that moves the name inside the window is unscheduled: an NDA-completion announcement, a partner disclosure, or sector-level biotech flow.
• ~2026-10-23 to 2026-10-27 — ESMO Congress, Madrid: OptimUM-01 (HLA*A2-positive mUM) and OptimUM-09 (neoadjuvant primary UM) darovasertib data, plus the Hengrui-sponsored IDE849 Phase 1 update.
• ~2026-11-03 (est.) — Q3 2026 results (pattern: Q1 on 2026-05-05, Q2 on 2026-08-04). The filing-completion language gets its next official update here.
• ~2026-12-31 (est.) — guided completion of the rolling darovasertib NDA under RTOR; also the stated goal to initiate the IDE849 registrational trial by year-end 2026 and to expand the IDE892 + IDE397 Phase 1.

Elapsed catalysts

• Q4 2026 (est.) — MTAP/CDKN2A, KRAS and pancreatic cancer R&D Day, per the 2026-08-04 release. (passed 22d ago)

What Would Change Our Mind

The structural break is the post-OptimUM-02 consolidation failing: a weekly close below $30 would put the stock halfway back to the $27.00 June offering price and would say the approval leg is being faded before the filing is even complete. Three non-price conditions carry equal weight. First, the rolling NDA not completing inside the guided H2 2026 window — an announcement absent by 2026-12-31, or softened language at the Q3 print, converts a filing story into a waiting story. Second, ESMO (Oct 23–27) coming and going with OptimUM-01 HLA*A2-positive results that do not support the label-expansion case management described on 2026-08-04, which would cap the commercial frame to the A2-negative first-line setting. Third, a change to the "into 2030" runway language alongside another sequential step-up in net loss from the Q2 level of $112.5M, which would put dilution back on the table despite ~$1.24B on hand. A downgrade from RBC, Truist or Wedbush — rather than another target trim — would mark the sell-side turning on the regulatory path itself.

Correlation Notes

• Beta source is clinical-stage oncology risk appetite (XBI complex) rather than any end-market cycle; with no product revenue, moves between now and ESMO are more likely to reflect sector flow than company data.
• M&A frame is set externally: GSK/Nuvalent at $10.6B announced 2026-06-09 is the live comparison for near-approval precision oncology assets, and IDEAYA's existing GSK Pol-theta and Servier darovasertib partnerships mean any acquirer headline in that cohort tends to re-price this name alongside it.
• IDE849 (SHR-4849, DLL3-TOP1 ADC with Hengrui) links the stock to the DLL3-ADC readout cycle in small-cell lung cancer; competitor DLL3 data at the same October ESMO window can move it independent of darovasertib.
• Not a retail-flow instrument: the shareholder register includes disclosed institutional holders (Baker Bros. Filed a 13G at 5.2%), and the price action since 2026-06-01 has tracked scheduled clinical and regulatory disclosure rather than message-board attention.